Drug Trial Radar · NCT04129164
A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome
Last checked: Nov 19, 2026Latest source record: Apr 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
183
Actual
Start
Dec 9, 2019
Primary completion
Sep 1, 2022
Study completion Mar 10, 2023
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Oct 16, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the efficacy, safety, and tolerability of VIB4920 (formerly MEDI4920) in adult participants with Sjögren's Syndrome (SS).
Conditions
- Sjögren's Syndrome
Interventions
VIB4920Drug
Intravenous Dose 1.
PlaceboDrug
Intravenous dose matched to VIB4920.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Population 1: Change From Baseline in ESSDAI at Day 169Time frame: Baseline and Day 169
- Population 2: Change From Baseline in ESSPRI at Day 169Time frame: Baseline and Day 169
Locations
62 sites in 12 countries. Site status is shown where the registry gives one.
Research Site
Fullerton, California
Research site
Upland, California
Research Site
Lawrenceville, Georgia
Research Site
Kansas City, Kansas
Research Site
Baltimore, Maryland
Research Site
Wheaton, Maryland
Research Site
Boston, Massachusetts
Research Site
Charlotte, North Carolina
Research Site
Durham, North Carolina
Research Site
Salisbury, North Carolina
Research Site
Wilmington, North Carolina
Research site
Duncansville, Pennsylvania
Research Site
Memphis, Tennessee
Research site
Dallas, Texas
Research Site
Houston, Texas
Research Site
Houston, Texas
Research Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Research Site
Bordeaux, France
Research Site
Brest, France
Research Site
Grenoble, France
Research Site
Paris, France
Research Site
Strasbourg, France
Research Site
Budapest, Hungary
Research Site
Debrecen, Hungary
Research Site
Gyula, Hungary
Research Site
Secunderabad, Andhra Pradesh, India
Research Site
Ahmedabad, Gujarat, India
Research Site
Bangalore, Karnataka, India
Research Site
Pune, Maharshtra, India
Research Site
Pune, Maharshtra, India
Research Site
Bhubaneswar, Odisha, India
Research Site
Chennai, Tamil Nadu, India
Research Site
Pisa, Italy
Research Site
Udine, Italy
Research Site
Milan, Lambardia, Italy
Research Site
Rome, Lazio, Italy
Research Site
Brescia, Province Of Brescia, Italy
Research Site
Perugia, Umbria, Italy
Research Site
Mexico City, Mexico
Research Site
Saltillo, Coahuila, Mexico
Showing 40 of 62 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.